1. Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation
- Author
-
John Parker Gott
- Subjects
medicine.medical_specialty ,Extracorporeal Circulation ,Serine Proteinase Inhibitors ,Inflammatory response ,030204 cardiovascular system & hematology ,Outcome (game theory) ,law.invention ,Fibrin Fibrinogen Degradation Products ,03 medical and health sciences ,0302 clinical medicine ,Aprotinin ,Coated Materials, Biocompatible ,law ,Adrenal Cortex Hormones ,medicine ,Cardiopulmonary bypass ,Humans ,Radiology, Nuclear Medicine and imaging ,Leukapheresis ,Quality of care ,Intensive care medicine ,Advanced and Specialized Nursing ,Inflammation ,Cardiopulmonary Bypass ,business.industry ,Heparin ,Extracorporeal circulation ,General Medicine ,medicine.disease ,Antifibrinolytic Agents ,Systemic inflammatory response syndrome ,Cardiac operations ,Treatment Outcome ,030228 respiratory system ,Costs and Cost Analysis ,Cardiology and Cardiovascular Medicine ,business ,Safety Research ,Filtration ,medicine.drug - Abstract
Most cardiac operations involve the use of extracorporeal circulation with its attendant systemic inflammatory response syndrome. Many anti-inflammatory strategies hold promise for reducing the associated morbidity of cardiopulmonary bypass. The application of pharmacological and mechanical strategies to control this inflammatory response now has demonstrable clinical benefit. The additional costs of these successful strategies are offset by the economic savings and improved quality of care.
- Published
- 2001